AcelRx Pharmaceuticals (NSDQ:ACRX) said today that the FDA accepted the company’s New Drug Application for its Dsuvia pain relief therapy. The federal watchdog set a target decision date for October 12 this year.
The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator to patients with moderate-to-severe acute pain resulting from trauma or injury.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA accepts AcelRx’s NDA for Dsuvia pain reliever appeared first on MassDevice.
from MassDevice http://ift.tt/2mma8qi
Cap comentari:
Publica un comentari a l'entrada